Stason Pharmaceuticals, Inc. has recalled 54, 131 bottles of Mercaptopurine Tablets, USP 50 mg, which are distributed under the Quinn Pharmaceuticals brand. The recall was issued because the medication failed dissolution testing at the nine-month mark, meaning the tablets were not dissolving as quickly as required by quality standards. This recall affects both 25-count and 250-count bottles from specific production lots with expiration dates in 2024. If you are taking this medication, you should consult with your healthcare provider or pharmacist regarding your treatment.
If the tablets do not dissolve properly, the body may not absorb the intended amount of the medication, which could potentially reduce the effectiveness of the treatment for the patient's condition.
You have 2 options:
Manufactured for Quinn Pharmaceuticals, Boca Raton, FL.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.